APA (7th ed.) Citation

ML, J., AE, P., RT, W., P, B., S, M., CH, S., . . . SM, L. (2025). Response to Lavin et al (2025)'s Paper: Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System. The Journal of investigative dermatology, 145(9), 2325. https://doi.org/10.1016/j.jid.2025.05.022

Chicago Style (17th ed.) Citation

ML, James, Pink AE, Woolf RT, Batty P, Mahil S, Smith CH, Whittaker S, and Langan SM. "Response to Lavin Et Al (2025)'s Paper: Cutaneous T-Cell Lymphoma After Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System." The Journal of Investigative Dermatology 145, no. 9 (2025): 2325. https://doi.org/10.1016/j.jid.2025.05.022.

MLA (9th ed.) Citation

ML, James, et al. "Response to Lavin Et Al (2025)'s Paper: Cutaneous T-Cell Lymphoma After Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System." The Journal of Investigative Dermatology, vol. 145, no. 9, 2025, p. 2325, https://doi.org/10.1016/j.jid.2025.05.022.